{"hands_on_practices": [{"introduction": "Before an sgRNA can be used in an experiment, it must first be synthesized. A common and powerful laboratory method for this is *in vitro* transcription (IVT), which uses a DNA template and an isolated enzyme to produce large quantities of RNA. This practice will test your understanding of how to design the DNA template that encodes a specific sgRNA, requiring you to correctly position the promoter sequence that initiates transcription and ensure the DNA sequence downstream will produce the desired RNA molecule. This exercise [@problem_id:2068635] builds a foundational skill, connecting the abstract sequence of an sgRNA to the concrete molecular biology required to create it.", "problem": "A researcher is designing a linear, double-stranded Deoxyribonucleic Acid (DNA) template to produce a specific single guide RNA (sgRNA) for a CRISPR-Cas9 experiment. The synthesis will be performed using an *in vitro* transcription (IVT) reaction with T7 RNA polymerase.\n\nThe key components and requirements are as follows:\n-   **T7 Promoter:** The specific double-stranded DNA sequence recognized by T7 RNA polymerase is $5'\\text{-TAATACGACTCACTATA-}3'$ on the coding strand. The polymerase binds to this promoter and initiates transcription on the template strand at the nucleotide immediately following the promoter sequence.\n-   **Desired sgRNA:** The final RNA product must have the sequence $5'\\text{-GCAUGCUAGCUGAUCGACUG-[Scaffold RNA]-}3'$, where `[Scaffold RNA]` represents the 80-nucleotide scaffold portion of the sgRNA.\n-   **DNA Encoding:** The DNA sequence that encodes the 20-nt spacer is $5'\\text{-GCATGCTAGCTGATCGACTG-}3'$. The DNA sequence on the coding strand that encodes the scaffold is denoted `[Scaffold DNA]`, and its complement on the template strand is denoted `[Compl. Scaffold DNA]`.\n\nWhich of the following double-stranded DNA constructs represents the correct template for producing the desired sgRNA? Note that in all options, the top strand is written in the 5' to 3' direction, and the bottom strand is its complement.\n\nA.\nTop: $5'\\text{-TAATACGACTCACTATAGCATGCTAGCTGATCGACTG[Scaffold DNA]-}3'$\nBottom: $3'\\text{-ATTATGCTGAGTGATATCGTACGATCGACTAGCTGAC[Compl. Scaffold DNA]-}5'$\n\nB.\nTop: $5'\\text{-TATAGTGAGTCGTATTAGCATGCTAGCTGATCGACTG[Scaffold DNA]-}3'$\nBottom: $3'\\text{-ATATCACTCAGCATAATCGTACGATCGACTAGCTGAC[Compl. Scaffold DNA]-}5'$\n\nC.\nTop: $5'\\text{-TAATACGACTCACTATACAGTCGATCAGCTAGCATGC[Scaffold DNA]-}3'$\nBottom: $3'\\text{-ATTATGCTGAGTGATATGTCAGCTAGTCGATCGTACG[Compl. Scaffold DNA]-}5'$\n\nD.\nTop: $5'\\text{-GCATGCTAGCTGATCGACTG[Scaffold DNA]-}3'$\nBottom: $3'\\text{-CGTACGATCGACTAGCTGAC[Compl. Scaffold DNA]-}5'$\n\nE.\nTop: $5'\\text{-GCATGCTAGCTGATCGACTG[Scaffold DNA]TAATACGACTCACTATA-}3'$\nBottom: $3'\\text{-CGTACGATCGACTAGCTGAC[Compl. Scaffold DNA]ATTATGCTGAGTGATAT-}5'$", "solution": "T7 RNA polymerase recognizes the promoter sequence on the coding strand given as $5'\\text{-TAATACGACTCACTATA-}3'$. Transcription initiates at the nucleotide immediately downstream ($+1$) of this promoter, reading the template strand and producing RNA that matches the coding strand downstream of the promoter with T replaced by U.\n\nThe desired RNA is $5'\\text{-GCAUGCUAGCUGAUCGACUG-[Scaffold RNA]-}3'$. Therefore, the coding DNA downstream of the promoter must read $5'\\text{-GCATGCTAGCTGATCGACTG-[Scaffold DNA]-}3'$, so that the transcribed RNA is obtained by a $T \\to U$ substitution: $5'\\text{-GCAUGCUAGCUGAUCGACUG-[Scaffold RNA]-}3'$. The template strand at the $+1$ site must be complementary, starting with C opposite the coding-strand G at $+1$.\n\nEvaluate each option:\n\n- Option A: Top strand contains the correct T7 promoter in the correct orientation, followed immediately by $5'\\text{-GCATGCTAGCTGATCGACTG-[Scaffold DNA]-}3'$, which encodes the required RNA. The bottom strand is the correct complement: the promoter complement is $3'\\text{-ATTATGCTGAGTGATAT-}5'$, and the spacer complement is $3'\\text{-CGTACGATCGACTAGCTGAC-}5'$, ensuring the template strand provides a C at $+1$ to produce a G in the transcript. This yields the desired sgRNA.\n\n- Option B: The top “promoter” is the reverse complement of the T7 promoter ($5'\\text{-TATAGTGAGTCGTATTA-}3'$), which is the wrong orientation on the coding strand; T7 RNA polymerase would not recognize this as the promoter on the coding strand. Incorrect.\n\n- Option C: The promoter is correct, but the sequence following it is $5'\\text{-CAGTCGATCAGCTAGCATGC-}3'$, which is the reverse complement of the desired spacer. The RNA produced would not match the intended sgRNA sequence. Incorrect.\n\n- Option D: There is no T7 promoter present. T7 RNA polymerase cannot initiate transcription. Incorrect.\n\n- Option E: The promoter is placed at the 3' end after the scaffold and in the wrong position relative to the transcript start, so transcription would not produce the desired RNA. Incorrect.\n\nTherefore, only option A provides the correct promoter orientation and the correct coding sequence downstream to produce the desired sgRNA.", "answer": "$$\\boxed{A}$$", "id": "2068635"}, {"introduction": "A perfectly designed sgRNA spacer that matches its target DNA sequence is necessary, but not sufficient, for the CRISPR-Cas9 system to work. The Cas9 nuclease has its own targeting requirement that is independent of the sgRNA's sequence. This thought experiment explores the critical role of the Protospacer Adjacent Motif (PAM), a short DNA sequence that must be present next to the target site in the genome for the Cas9 protein to bind and cut. Understanding this \"licensing\" mechanism is non-negotiable for successful sgRNA design, as it explains why a guide might be effective in one species but not another, even if the gene sequence seems identical [@problem_id:2068645].", "problem": "A researcher is using the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 genome editing system derived from *Streptococcus pyogenes* (SpCas9). A key component of this system is the single guide RNA (sgRNA), an engineered molecule comprising two main parts: a ~20-nucleotide 'spacer' region that determines the target DNA sequence through base pairing, and a 'scaffold' region that binds to the SpCas9 protein. The SpCas9 protein will only cleave a DNA target if, in addition to the spacer binding, it recognizes a specific sequence known as the Protospacer Adjacent Motif (PAM). For SpCas9, the canonical PAM sequence is $5'\\text{-NGG-}3'$ on the non-target DNA strand, immediately downstream of the region the spacer binds to.\n\nThe researcher has designed an sgRNA that successfully targets and knocks out a specific gene in mouse cells. Upon sequencing, the researcher finds that the 20-nucleotide DNA sequence targeted by the sgRNA's spacer is perfectly conserved in the homologous gene in human cells. However, when the researcher introduces the same SpCas9 protein and the same sgRNA into human cells, the editing experiment completely fails, with no modification of the human gene observed.\n\nAssuming no issues with experimental delivery into the cells, which of the following provides the most direct and crucial molecular explanation for this failure?\n\nA. The sgRNA scaffold region, while functional in mouse cells, is recognized as a foreign RNA and degraded by the innate immune system in human cells.\n\nB. The region of the human gene immediately downstream of the 20-nucleotide target sequence lacks the required $5'\\text{-NGG-}3'$ PAM sequence.\n\nC. The human gene is significantly larger in total kilobases than the mouse gene, which sterically hinders the binding of the relatively small CRISPR-Cas9 complex.\n\nD. The codon usage bias of the human gene is different from the mouse gene, interfering with the DNA recognition process by the sgRNA.\n\nE. The sgRNA was designed using a mouse-specific algorithm that incorporates epigenetic markers, rendering it ineffective on the different epigenetic landscape of human chromatin.", "solution": "1) For SpCas9 from Streptococcus pyogenes to cleave DNA, two conditions must be met simultaneously: (i) the spacer region of the sgRNA must base-pair with the complementary 20-nucleotide protospacer sequence in the target DNA, and (ii) an appropriate PAM sequence, specifically $5'\\text{-NGG-}3'$ for SpCas9, must be present on the non-target DNA strand immediately downstream of the protospacer. Condition (ii) is an absolute requirement for Cas9 binding and nuclease activation; without the PAM, Cas9 does not stably bind or cleave, even if there is perfect spacer-protospacer complementarity.\n\n2) The observation that the 20-nucleotide target sequence is perfectly conserved between mouse and human indicates that condition (i) is satisfied in both species. The complete failure of editing in human cells, despite identical spacers and functional SpCas9, therefore points to a failure of condition (ii): the required $5'\\text{-NGG-}3'$ PAM adjacent to the protospacer is likely absent (or altered) in the human locus.\n\n3) Evaluating the options against this mechanistic requirement:\n- Option B states that the region immediately downstream of the 20-nucleotide target in the human gene lacks the required $5'\\text{-NGG-}3'$ PAM. This directly explains the failure, as PAM absence categorically prevents Cas9-mediated cleavage despite perfect target matching.\n- Option A proposes species-specific degradation of the sgRNA scaffold by human innate immunity. The commonly used SpCas9 sgRNA scaffold functions across mammalian cells, and innate immune recognition is neither a specific nor a necessary explanation for complete loss of editing under otherwise successful delivery conditions; moreover, it is not the key molecular determinant of Cas9 activity at a given locus.\n- Option C invokes gene size as a steric hindrance to Cas9 binding. Total gene length in kilobases does not impede Cas9’s sequence-specific recognition; Cas9 locates targets via diffusion and sequence scanning, independent of gene length.\n- Option D refers to codon usage bias of the gene, which affects protein translation from mRNA and has no bearing on DNA recognition by the RNA-guided nuclease.\n- Option E appeals to species-specific epigenetic differences. While chromatin state can modulate accessibility and efficiency, it is not an absolute requirement in the way a PAM is; many targets in human chromatin are editable if PAM is present. Epigenetic differences do not provide as direct and crucial an explanation as PAM absence.\n\n4) Therefore, the most direct and crucial molecular explanation consistent with the data and Cas9 mechanism is the absence of the required PAM adjacent to the conserved protospacer in the human genome, as stated in Option B.", "answer": "$$\\boxed{B}$$", "id": "2068645"}, {"introduction": "When designing an sgRNA for therapeutic purposes, the goal is not just to edit a gene effectively, but to do so with the highest possible safety. Unintended edits at other locations in the genome, known as off-target effects, can have dangerous consequences. This scenario presents a realistic trade-off between on-target efficacy (how well the guide works) and off-target risk (how likely it is to cause unintended mutations). This decision-making exercise [@problem_id:2068620] moves beyond basic design rules into the realm of risk assessment, highlighting the paramount importance of safety in clinical applications and forcing you to weigh competing design metrics.", "problem": "A research team at a biopharmaceutical company is developing a gene therapy for a severe genetic disorder using the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 system. The therapeutic strategy involves using a single guide RNA (sgRNA) to direct the Cas9 nuclease to a specific target sequence within the human genome to disable a faulty gene. The team has designed and computationally evaluated two candidate sgRNAs, sgRNA-Alpha and sgRNA-Beta.\n\nThe properties of the two candidates are as follows:\n\n*   **sgRNA-Alpha**:\n    *   On-target activity score: 92% (predicts high efficiency in cutting the intended DNA sequence).\n    *   Off-target profile: Bioinformatic analysis predicts 1 potential off-target site with only 2 nucleotide mismatches located in the promoter region of an important metabolic gene, and 4 other potential off-target sites with 3 nucleotide mismatches each in various gene-coding regions.\n\n*   **sgRNA-Beta**:\n    *   On-target activity score: 65% (predicts moderate efficiency in cutting the intended DNA sequence).\n    *   Off-target profile: Bioinformatic analysis predicts only 1 potential off-target site. This site has 4 nucleotide mismatches and is located in an intergenic region (a \"gene desert\") far from any known genes or regulatory elements.\n\nGiven that the goal is to develop a safe and effective therapy for human patients, which of the following represents the most prudent choice for the team to advance into further preclinical development, and what is the best justification?\n\nA. sgRNA-Alpha, because achieving the highest possible on-target editing efficiency is the primary goal to ensure the therapy is effective for the largest number of a patient's cells.\n\nB. sgRNA-Beta, because minimizing the risk of unintended and potentially dangerous off-target mutations is the highest priority in therapeutic applications, even if it means sacrificing some on-target efficiency.\n\nC. sgRNA-Alpha, because the off-target effects are only potential and can likely be eliminated by optimizing the delivery method of the CRISPR-Cas9 components into the cells.\n\nD. sgRNA-Beta, because a lower on-target score is generally indicative of a more stable and reliable sgRNA-Cas9 complex.", "solution": "We want the most prudent sgRNA for a human therapeutic application, which requires prioritizing patient safety (minimizing off-target risk) over maximal on-target activity, provided that sufficient efficacy can still be achieved. Key principles:\n\n1) In therapeutic genome editing, safety is prioritized over peak efficiency. Off-target cleavage can cause harmful mutations, especially in coding regions or regulatory elements (such as promoters) of essential genes. Therefore, both the likelihood of off-target cutting and the functional importance of the off-target site’s genomic context are critical.\n\n2) Off-target likelihood correlates inversely with mismatch count and context: sites with fewer mismatches (for example, 2 mismatches) are generally at higher risk for Cas9 cleavage than sites with more mismatches (for example, 4 mismatches), all else equal. Moreover, off-targets in promoters or gene-coding regions carry higher functional risk than those in intergenic “gene desert” regions.\n\n3) Comparing the candidates:\n- sgRNA-Alpha has on-target activity approximately $0.92$ but carries a predicted off-target with only 2 mismatches in the promoter of an important metabolic gene, plus four predicted off-targets with 3 mismatches in various coding regions. This combination indicates a nontrivial probability of functionally consequential off-target edits.\n- sgRNA-Beta has on-target activity approximately $0.65$ and only a single predicted off-target with 4 mismatches in an intergenic gene desert, implying both a lower likelihood of cleavage and a lower chance of functional consequences even if cleavage occurs.\n\n4) The trade-off favors sgRNA-Beta: while $0.65$ on-target activity is lower than $0.92$, it is often sufficient for therapeutic benefit, especially with optimization of delivery, dosing, and editor choice (for example, high-fidelity Cas9 variants, chemically modified sgRNAs, or improved delivery systems). In contrast, Alpha’s predicted off-targets present substantial safety concerns that are not guaranteed to be mitigated simply by optimizing delivery, because sequence-determined off-targeting is intrinsic to the guide-target complementarity.\n\n5) Evaluating the answer choices:\n- A is not prudent because it prioritizes maximal efficiency over a high-risk off-target profile in sensitive genomic contexts.\n- B is correct because minimizing potentially dangerous off-target mutations is the highest priority in human therapeutics, and Beta’s off-target profile is both less likely and less consequential.\n- C is incorrect because delivery optimization does not reliably eliminate sequence-driven off-target risks, particularly at low-mismatch sites in critical regions.\n- D is incorrect because a lower on-target score does not imply a more stable or reliable sgRNA-Cas9 complex; it simply predicts lower cutting efficiency.\n\nTherefore, the most prudent choice is sgRNA-Beta with the safety-first justification in B.", "answer": "$$\\boxed{B}$$", "id": "2068620"}]}